Brief: Anaptys Announces New Positive Phase 2B Trial Results For Rosnilimab In Rheumatoid Arthritis
29/10/2025 14:35
Oct 29 (Reuters) - AnaptysBio Inc ANAB.O: ANAPTYS ANNOUNCES NEW POSITIVE PHASE 2B TRIAL RESULTS FOR ROSNILIMAB IN RHEUMATOID ARTHRITIS AT ACR LATE-BREAKING ORAL PRESENTATION ANAPTYSBIO INC - ROSNILIMAB SHOWS EFFICACY IN RA WITH CDAI REMISSION ANAPTYSBIO INC - ROSNILIMAB WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS Source text: ID:nGNXZgw4h Further company coverage: ANAB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AnaptysBio
See all newsFirst Tracks Biotherapeutics up after $200 mln equity raise
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Brief: Anaptys Announces Second Quarter And Transitional Fiscal Year 2026 Financial Results And Provides Business Update
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties